没有可检测的多糖体的IV型糖原储存疾病:广泛基因组的重要性
Agata Oliwa1, Gavin Langlands2, Anna Sarkozy3
1Undergraduate Medical School, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, UK; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Neuromuscular disorders : NMD
|August 19, 2023
概括
由GBE1基因突变引起的第四类葡萄糖储存疾病 (GSD IV),可以在没有典型的多糖体的情况下出现. 这项研究扩大了对GSD IV的理解.
科学领域:
- 遗传学和分子生物学
- 神经肌肉疾病 神经肌肉疾病
- 代谢疾病 代谢疾病
背景情况:
- 糖原储存疾病类型IV (GSD IV) 是一种遗传疾病,由糖原分枝酶1 (GBE1) 基因的突变引起.
- 它的典型特征是多糖体在包括肝脏和肌肉在内的各种组织中的积累.
- GSD IV的神经肌肉表现不太常见,其诊断特征可能是可变的.
研究的目的:
- 描述三种类型IV的神经肌肉糖原储存疾病的临床和病理发现.
- 扩大已知的GBE1突变的表型谱.
- 突出诊断方面的挑战,特别是肌肉活检中缺乏多糖体.
主要方法:
- 一系列病例报告了三名疑似神经肌肉GSD IV的患者.
- 临床评估包括神经学检查,发育里程碑和呈现症状.
- 对肌肉活检结果的审查,特别注意多糖体的存在或不存在.
主要成果:
- 报告的三例病例中,没有一个在肌肉活检上显示出多糖体,这挑战了关键的诊断标准.
- 患者表现出了一系列神经肌肉症状,包括运动发育延迟,关节,低血压,呼吸困难和四肢腰带虚弱.
- 在所有病例中都观察到一个一致的轴弱,近端上肢弱与头巾翼,以及较轻微的近端下肢弱的模式.
结论:
- GBE1基因的突变可以导致神经肌肉GSD IV,其表型包括先天性肌肉病和四肢腰带软弱.
- 肌肉活检上没有特征性的多糖体并不排除GSD IV的诊断.
- 在无法解释的神经肌肉疾病的差异诊断中,即使没有病理学组织学发现,也应该考虑GSD IV.
相关概念视频
Glucose Transporters
22.9K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.9K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Inborn Errors of Metabolism
194
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
194
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211


